MUMO1

Primary indication:

  • Pain.

Development goals:

  • Better benefit-risk than standard treatment.

The project has been supported by the Spanish Ministry of Economy, Industry and Competitiveness through the Centre for the Development of Industrial Technology (CDTI) and has been co-financed by the European Union through the European Regional Development Fund (ERDF).

 

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.